JS007
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
|
IL-2 |
JS007 binds to CHO-CTLA-4 cells with an EC50 of 0.22 μg/mL, and its binding affinity is higher than that of the control antibody Ipilimumab (HY-P9901)[1].
JS007 binds to recombinant CTLA-4 with a KD value of 0.21 nM, and its binding affinity is significantly higher than that of the control antibody Ipilimumab[1].
JS007 blocks the interaction between CTLA-4 and B7-1 in CHO-CTLA-4 cells, with an IC50 of 1.096 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
JS007 (0.03-0.1 mg/kg; i.p.; twice weekly) provides substantial in vivo tumor suppression efficacy in H22 syngeneic tumor-bearing human CTLA-4 knock-in BALB/c mice, with statistically significant reductions in tumor volume and weight compared to the isotype control group (p < 0.01)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6-CTLA4tm1(CTLA4)/Bcgen[1]
-
Dosage:0.1 mg/kg; 1 mg/kg
-
Administration:i.p.; twice weekly
-
Result:Showed significantly lower tumor volume and weight compared to the isotype control group at 1 mg/kg, with values also significantly lower than the ipilimumab 1 mg/kg group (p < 0.05).
Showed significantly lower tumor volume and weight compared to the isotype control group at 0.1 mg/kg, but higher tumor volume and weight than the 1 mg/kg JS007 group.
-
Animal Model:BALB/c-Ctla4em1(hCTLA4)Smoc[1]
-
Dosage:0.03 mg/kg; 0.1 mg/kg
-
Administration:i.p.; twice weekly
-
Result:Showed substantially lower tumor volume and weight compared to the isotype control group at 0.1 mg/kg (p < 0.01).
Showed significantly lower tumor volume and weight compared to the isotype control group at 0.03 mg/kg, but higher tumor volume and weight than the 0.1 mg/kg JS007 group.
Showed a better tumor inhibition trend than ipilimumab at 0.1 mg/kg, though the difference was not statistically significant (p > 0.05).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
CTLA4
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[JS007]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JS007 Related Classifications
HY-P991960 Related Classifications
Powered by Bioz